author-photo

Suneel D. Mundle

Rush University Medical Center

72

Papers

1922

Citations

Citation Trend

Filter By

Papers (59) Sort By

Journal Conference Others

Mathematical modeling of bone marrow - peripheral blood dynamics in the disease state based on current emerging paradigms, part II

2019 Journal of Theoretical Biology
Show All
- Source
- Cite
- Save
Citations (2)
Mathematical modeling of bone marrow--peripheral blood dynamics in the disease state based on current emerging paradigms, part I.

2016 Bellman Prize in Mathematical Biosciences
Show All
- Source
- Cite
- Save
Citations (6)
Biological characteristics of myelodysplastic syndrome patients who demonstrated high versus no intramedullary apoptosis.

2009 European Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (28)
An assessment of erythroid response to epoetin α as a single agent versus in combination with granulocyte– or granulocyte-macrophage–colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach†

2009 Cancer
Show All
- Source
- Cite
- Save
Citations (49)
Relationship Between Epoetin Alfa (EPO) Treatment and Serum Hepcidin Levels in Anemic Patients with Rheumatoid Arthritis (RA)

2008 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis

2008 Annals of Hematology
Show All
- Source
- Cite
- Save
Citations (110)
Comparison of erythroid response (ER) rates to epoetin alfa (EPO) alone or in combination versus non-erythropoiesis-stimulating agents (non-ESAs) in treatment-naive anemic MDS patients: A meta-analysis approach

2008 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Early Normalization of Serum Free Light Chain Is Associated with Prolonged Time to Progression Following Bortezomib ± Pegylated Liposomal Doxorubicin Treatment of Relapsed/Refractory Multiple Myeloma.

2007 Blood
Show All
- Source
- Cite
- Save
Citations (4)
The Prolonged Time to Progression with Pegylated Liposomal Doxorubicin + Bortezomib Versus Bortezomib Alone in Relapsed or Refractory Multiple Myeloma Is Unaffected by Extent of Prior Therapy or Previous Anthracycline Exposure.

2007 Blood
Show All
- Source
- Cite
- Save
Citations (11)
Pegylated Liposomal Doxorubicin (PLD) in Combination with Bortezomib (B) May Provide Therapeutic Advantage for High-Risk Multiple Myeloma Patients Relapsing within 12 Months of Stem Cell Transplant.

2007 Blood
Show All
- Source
- Cite
- Save
Citations (4)